The global immunohistochemistry market size was valued at USD 2.33 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030. Increasing implementation of automation and machine learning in immunohistochemistry (IHC), coupled with the introduction of technologically advanced immunohistochemistry solutions, is expected to significantly drive the market throughout the forecast period. Advancements in IHC protocols have boosted its demand to a significant level in disease diagnosis. In addition, the rise in product approvals and the launch of technologically advanced immunohistochemistry systems for disease diagnosis are further propelling the market growth.
For instance, in August 2021, the FDA approved Roche’s VENTANA MMR RxDx Panel to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy. Companies continue to launch novel products to strengthen their market position, which leads to revenue generation. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit to detect and profile biomarkers and cell populations in tissue-based research. This kit can be utilized in combination with other detection kits, expanding the multiplexing capacity of in situ hybridization and immunohistochemistry. Similarly, in March 2023, Paige announced the inclusion of artificial intelligence (AI) algorithms of Mindpeak's for immunohistochemistry biomarker quantification on the company’s platform. Mindpeak, a software company specializing in image analysis, has contributed AI algorithms designed for the analysis of immunohistochemistry slides of lung and breast tissue, which are now available on the platform. IHC technology is limited to single parametric evaluations of a sample.
Newer techniques such as multiplexed IHC, however, allow multiparametric and detailed analysis from a single tissue segment by utilizing advanced methods of mass spectrometric detection. Multiplexed IHC helps address the technical challenges posed by the labeled fluorescence detection-based method, thereby spurring the market revenue. The growing elderly population in both developed and emerging nations would favorably impact the Immunohistochemistry market. The frequency of age-related disorders is expected to rise dramatically as the global geriatric population grows significantly.RT-PCR, immunohistochemistry, and an electron microscope were used to detect the virus, indicating that the effect of SARS-CoV-2 is not limited to the lungs.
The antibodies segment dominated the market in 2022 and accounted for the largest share of 40.96% owing to the vital usage of antibodies in disease diagnosis and drug testing. The monoclonal antibodies and antibody-related products such as Fc-fusion, antibody fragments, and antibody-drug conjugates have become the dominating product class in terms of usage rate. The antibodies are applied across a wide range of applications such as pathology, neuropathology, and hematopathology.
Kits are anticipated to expand at the fastest CAGR throughout the forecast period. The use of kits reduces a lot of efforts during the IHC procedure as it eliminates the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample. The compact nature and ease of use offered by the products under this segment are expected to drive the segment. IHC kits are commonly utilized in academic institutions and research laboratories that require these products in small quantities for carrying out research. Thus, rising research programs that involve the use of IHC assays are contributing to the segment growth.
Based on applications, the global market has been further bifurcated into diagnostics and research segments. The diagnostics application segment accounted for the largest revenue share of more than 69.16% in 2022 and is anticipated to maintain its lead over the forecast period. Immunohistochemistry (IHC) tests are widely used for the diagnosis of a wide range of chronic conditions, such as cancer, cardiovascular diseases, infectious diseases, diabetes mellitus, autoimmune diseases, and nephrological diseases. Furthermore, the growing prevalence of chronic diseases is anticipated to drive the diagnostics segment.
According to data published by the American Cancer Society, around 1.9 million new cancer cases are expected to be reported in the U.S. in 2021. With a rise in the number of cancer cases, the need for IHC techniques for rapid and efficient diagnosis is high. Thus, rising R&D activities by pharmaceutical companies for research and development of innovative drugs are anticipated to increase the demand for IHC solutions and drive the segment. For instance, in July 2021, NHS England declared a novel innovative medicine fund to accelerate the research development of new drugs.
Based on end-uses, the global market has been further sub-segmented into hospitals & diagnostic laboratories, research institutes, and others. In 2022, the hospitals and diagnostic laboratories segment dominated the market and accounted for the largest share of more than 70.76% of the overall revenue. This growth was attributed to the high volume of IHC tests carried out in hospital settings. Furthermore, with the constant changes in the healthcare industry, the need for hospitals with advanced facilities has also increased. This, in turn, is also expected to increase the revenue flow in this segment.
Research institutes are expected to register a lucrative CAGR during the forecast period. This is because the technique offers several advantages over conventionally used staining techniques in pharmaceutical R&D. For instance, a human-specific IHC-approved VISTA rabbit monoclonal antibody, manufactured by Cell Signaling Technology, is available for biomedical research use. The growth can be also attributed to the wide adoption of IHC techniques in drug testing by research institutes. The technique allows the evaluation of biomarker distribution and localization and different protein expressions in varied biological tissue sections, which is conducted in research settings. Research institutes play a significant role by applying IHC techniques in drug development for the evaluation of drug efficacy tests.
Based on region, the global market has been further sub-categorized into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 and accounted for the largest share of more than 38.39%. of the global revenue. Key factors contributing to the regional market growth include the presence of major market players, easy availability of IHC solutions, higher adoption of technologically advanced IHC instruments, and entry of newer IHC solutions.
For instance, in June 2021, PathAI, a U.S.-based developer of AI-powered technology for pathological applications, showcased a machine learning-based quality control tool, designed for HER2 testing in breast cancer, at the American society of clinical oncology virtual scientific program 2021. Asia Pacific is expected to witness the fastest growth during the forecast period. This is primarily due to the expansion of the geographic footprint of the global players in the Asian markets. Furthermore, a large patient pool in countries such as India and China provides a large number of clinical subjects to carry out IHC R&D assays, resulting in revenue growth.
With the rising demand for IHC assays in cancer diagnostics, the key players are undertaking various strategic initiatives in the field of immunohistochemistry, including new product launches, mergers & acquisitions, and regional expansion, to meet the market needs.
For instance, in March 2023, Aptamer Group launched a new reagent solution, Optimer-Fc for use in automated immunohistochemistry workflows. The company expects this launch to open new avenues for emerging biomarkers in diagnostics and research. In addition, in January 2021, Abcam and Shuwen Biotech (Shuwen) entered into a strategic alliance for developing and commercializing companion diagnostics (CDx). Under the agreement, Abcam is providing recombinant rabbit monoclonal antibodies to Shuwen Biotech for further immunohistochemical verification. Some prominent players in the global immunohistochemistry market include:
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Bio-Rad Laboratories, Inc.
Cell Signaling Technology, Inc.
Agilent Technologies, Inc.
Market size value in 2023
USD 2.36 billion
Revenue forecast in 2030
USD 3.50 billion
CAGR of 5.8% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, application, end-use, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; PerkinElmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Bio SB; Abcam plc.; Agilent Technologies, Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global immunohistochemistry market report on the basis of product, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Slide Staining System
Tissue Processing Systems
Blocking Sera & Reagents
Application Outlook (Revenue, USD Million, 2018 - 2030)
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals & Diagnostic Laboratories
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global immunohistochemistry market size was estimated at USD 2.33 billion in 2022 and is expected to reach USD 2.36 billion in 2023.
b. The global immunohistochemistry market is expected to grow at a compound annual growth rate of 5.8% from 2023 to 2030 to reach USD 3.50 billion by 2030.
b. Antibodies dominated the immunohistochemistry (IHC) market with a share of 40.96% in 2022. This is attributable to their continuous usage in IHC procedures for disease diagnosis and drug testing.
b. Some key players operating in the IHC market include Abcam plc; Agilent Technologies; Bio SB; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; F. Hoffmann-La Roche AG; Merck KGaA; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc.
b. Key factors that are driving the IHC market growth include the emergence of multiplexed immunohistochemistry, the implementation of automation and machine learning in IHC, and an increase in the prevalence of cancer.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."